Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancer Discovery"
DOI: 10.1158/2159-8290.cd-22-0968
Abstract: NVL-520, a selective macrocyclic inhibitor of ROS1, demonstrated antitumor activity in patient case studies of ROS1 inhibitor–refractory lung cancers without observed neurologic toxicities attributed to TRK inhibition.
read more here.
Keywords:
inhibitor ros1;
nvl 520;
selective trk;
520 selective ... See more keywords